Skip to main content
SpringerLink
Log in

Regulatory Issues in the Development and Marketing of Lateral Flow Immunoassays

  • Chapter
  • First Online:
Lateral Flow Immunoassay

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. “General Information Concerning Patents”. US Patent and Trademark Office. www.uspto.gov/go/pac/doc/general/

  2. “Rapid Lateral Flow Test Strips: Considerations for Product Development”. Millipore Inc., 2006.

    Google Scholar 

  3. “Mandatory Guidelines and Proposed Revisions to Mandatory Guidelines for Federal Workplace Drug Testing Programs; Notices”. Federal Register, Vol. 69, No. 71 pp. 19644–19673.

    Google Scholar 

  4. “Procedures for Specimen Collection and the Detection and Quantitation of Drugs of Abuse in Urine”, by Australian/New Zealand Standard. AS/NZS 4308:2008, March 19, 2008.

    Google Scholar 

  5. “Design Control Guidance For Medical Device Manufacturers”. FDA Center for Devices and Radiological Health, March 11, 1997, www.fda.gov/cdrh/comp/designgd.pdf

  6. “Basic Facts about Trademarks”. US Patents and Trademark Office. www.uspto.gov/web/offices/tac/doc/basic

  7. “Getting to Market with a Medical Device” US Food and Drug Administration. www.fda.gov/CDRH/DEVADVICE/3122

  8. Smith, K. and Kates, J. (1966) Regulatory hurdles in bringing an in vitro diagnostic device to market. Clin. Chem. 42(9):1556–1557.

    Google Scholar 

  9. “CLIA – Clinical Laboratory Improvement Amendments”. US Food and Drug Administration. www.fda.gov/CDRH/clia/

  10. “Public Health Service; CLIA Program; Categorization of Waived Test”. Department of Health and Human Services, Health Care Financing Administration, Federal Register 42 CFR 493.15 (b) and 42 CFR 493.15 (c), September 13, 1995, Vol. 60, No. 177, pp. 47534–47543.

    Google Scholar 

  11. “Guidance Notes on In Vitro Diagnostic Medical Devices Directive 98/79/EC”. Competent Authority (UK), February 2006, www.mhra.gov.uk/Howweregulate/Devices/InVitroDiagnosticMedical DevicesDirective/index.htm

  12. “Food and Drug Administration, Title 21, Part 820 Quality System Regulation”. 21CFR820.100

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Branan Medical Corporation, 140, Technology Drive, Suite 400, Irvine, CA, USA

    Raphael C. Wong

Authors
  1. Raphael C. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raphael C. Wong .

Editor information

Editors and Affiliations

  1. Branan Medical Corporation, Muirlands Rd. 10015, Irvine, 92618, U.S.A.

    Raphael Wong

  2. School of Medicine, Dept. Immunology & Microbiology, Wayne State University, E. Canfield Ave. 540, Detroit, 48201, U.S.A.

    Harley Tse

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Wong, R.C. (2009). Regulatory Issues in the Development and Marketing of Lateral Flow Immunoassays. In: Wong, R., Tse, H. (eds) Lateral Flow Immunoassay. Humana Press. https://doi.org/10.1007/978-1-59745-240-3_11

Download citation

Publish with us

Policies and ethics

Search

Navigation